Letter Urging Prohibition of Pharmacy Benefit Managers from Owning or Operating Pharmacies

April 14, 2025

The letter urges Congress to pass legislation prohibiting PBMs and their parent companies from owning or operating pharmacies to foster fair competition and protect consumers

Read More →

Bipartisan coalition of attorneys general call for Congress to require surgeon general warning on social media platforms

September 10, 2024

The National Association of Attorneys General (NAAG) sent a letter to Congress calling on lawmakers to pass legislation requiring a U.S. surgeon general warning on all algorithm-driven social media platforms. The letter comes amidst growing scrutiny of social media companies for their role in generational harm to young people’s mental health.

Read More →

Attorneys General Urge Congress to Appropriate Funding in the FY2025 Budget for Legal Services Corporation

April 29, 2024

A bipartisan coalition of 39 state and territory attorneys general urge leaders of the U.S. House and Senate Appropriations Committees to allocate robust funding for the nonprofit Legal Services Corporation (LSC) in the FY2025 budget. LSC supports equal access to justice by awarding grants to nonprofit organizations that provide civil legal services to those in…

Read More →

Bipartisan Coalition of Attorneys General Express Support for the G.U.A.R.D. VA Act

August 9, 2023

A bipartisan coalition of 44 attorneys general express support for the passage of legislative proposals included in Governing Unaccredited Representatives Defrauding (G.U.A.R.D.) Veterans Affairs (VA) Benefits Act. In a letter to congressional leaders, the attorneys general explain that the passing of the bipartisan legislation would hold unaccredited and unregulated actors accountable for targeting and preying…

Read More →

Attorneys General Urge Congress to Appropriate Funding for Legal Services Corporation

May 11, 2023

A bipartisan coalition of 37 state and territory attorneys general urge leaders of the U.S. House and Senate Appropriations Committees to allocate robust funding for the nonprofit Legal Services Corporation (LSC) in the FY2024 budget. LSC supports equal access to justice by awarding grants to nonprofit organizations that provide civil legal services to those in…

Read More →

AGs to Congress: Provide Funding for the Legal Services Corporation

April 29, 2022

The National Association of Attorneys General (NAAG) sent a letter to Congress to support beneficent funding for the Legal Services Corporation (LSC). The LSC provides critical legal assistance to low-income Americans, helping families in need across the country. Nonprofit legal aid programs funded by the federal program provide services to millions of Americans annually, reaching…

Read More →

Attorneys General Support The Public Safety Officer Act of 2022

April 25, 2022

NAAG is urging Congress to pass The Public Safety Officer Support Act of 2022. The legislation addresses gaps in support for public safety officers who suffer from post-traumatic stress disorder (PTSD) associated with the high-risk nature of their jobs. In the letter signed by 53 attorneys general, the attorneys general praise the work of public…

Read More →

NAAG Supports Funding for Legal Services Corporation (LSC)

April 29, 2021

LSC funding has also fostered public-private partnerships between legal aid
organizations and private firms and attorneys across the country which donate their
time and skills to assist residents in need. Nationwide, 132 independent nonprofit
legal aid programs rely on this federal funding to provide services to nearly two
million of our constituents on an annual basis.

Read More →

Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)

October 9, 2020

Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →